Global AI in Oncology Market - 2025-2033
Global AI in Oncology Market Size - Industry Trends & Outlook
The global AI in oncology market size reached US$ 2.43 Billion in 2024 and is expected to reach US$ 22.85 Billion by 2033, growing at a CAGR of 25.3% during the forecast period 2025-2033.
The global AI in oncology market is witnessing rapid growth, fueled by advancements in artificial intelligence technologies, increased cancer prevalence, and a rising emphasis on personalized medicine. Pharmaceutical and healthcare companies invest heavily in AI-driven diagnostic tools, treatment planning systems, and drug discovery platforms. Regulatory bodies also support this shift, with approvals for AI-based cancer detection devices becoming more common.
Collaboration between medical institutions, technology providers, and research organizations is accelerating the integration of AI into clinical practice. Public awareness about early cancer detection is contributing to higher screening rates, while AI enhances the accuracy and speed of diagnosis.
North America currently dominates the global AI in oncology market, driven by its advanced healthcare infrastructure, strong regulatory support, and high adoption of AI technologies in clinical settings. The presence of leading technology firms and frequent collaborations between healthcare providers and AI developers have further accelerated market growth in the region.
Global AI in Oncology Market Dynamics: Drivers & Restraints
Advancements in Artificial Intelligence and Machine Learning are Expected to Drive the AI in Oncology Market
Advancements in artificial intelligence (AI) and machine learning are playing a pivotal role in the growth of the oncology market by boosting diagnostic precision, enabling more personalized treatment strategies, and speeding up the drug discovery process. For example, in September 2024, Immunai Inc. entered into a multi-year partnership with global pharmaceutical leader AstraZeneca. The collaboration will use Immunai’s proprietary AI platform, known as IDE, to support clinical decision-making and increase the chances of success in drug development efforts.
Similarly, Onc.AI is harnessing a leading real-world oncology dataset to build a robust pipeline of AI models aimed at realizing the full potential of precision oncology.
Meanwhile, companies are collaborating to advance their research in incorporating AI in the early diagnosis of various cancers. For instance, in April 2025, Optellum signed an agreement with Bristol Myers Squibb to use AI for early detection and precision lung cancer care. According to the agreement, Optellum will use its AI-powered imaging and clinical decision support platform to assess the real-world impact on patient outcomes.
Data Privacy and Security Concerns are Expected to Hinder the AI in Oncology Market
Data privacy and security concerns are expected to significantly hamper the growth of the AI in oncology market, as the field heavily relies on large volumes of sensitive patient data for effective algorithm training and deployment. The use of such data raises critical challenges around compliance with regulations like HIPAA in the U.S. and GDPR in Europe, which strictly govern how personal health information can be collected, processed, stored, and shared. Any breach or misuse of this data can lead to legal liabilities, loss of patient trust, and reputational damage for healthcare providers and AI developers.
Global AI in Oncology Market Segment Analysis
The global AI in oncology market is segmented based on component type, cancer type, application, end user and region.
Component Type:
The software segment is expected to hold 46.7% of the global AI in Oncology Market
The software segment is expected to dominate the AI in oncology market due to its pivotal role in enabling accurate diagnostics, personalized treatment planning, and efficient clinical workflows. This dominance is reflected in its substantial market share, driven by growing adoption across hospitals and research institutions. Recent innovations further validate this trend.
For instance, in October 2023, Philips’ AI-powered MR imaging technology, combined with Quibim’s AI-driven image analysis software, is designed to support clinicians in providing quicker and more efficient prostate cancer care, addressing workforce shortages, and helping to reduce overall healthcare costs.
Similarly, in August 2023, MVision AI announced the release of version 1.2.4 of its guideline-based automatic segmentation software, now rebranded as Contour+. This updated version introduces new contouring models and enhanced Region-Of-Interest (ROI) operations, expanding its clinical applications. With this release, MVision AI aims to further improve the accuracy and consistency of medical contouring, offering a more advanced and standardized solution for clinicians. The model also allows for standardized contouring required in clinical trials and cancer research.
Such advancements demonstrate how AI software solutions are becoming integral to oncology workflows, making the segment the core driver of technological transformation in cancer care.
Global AI in Oncology Market Geographical Analysis
North America was valued at US$ 0.96 billion in 2024 and is estimated to reach US$ 9.07 billion by 2033, growing at a CAGR of 31.3%
North America is expected to dominate the AI in oncology market due to its advanced healthcare infrastructure, strong research ecosystem, and a high burden of cancer cases. This leadership is reinforced by recent innovations that are rapidly transforming cancer care. For instance, in January 2024, DermaSensor Inc. received FDA clearance for its innovative AI-powered medical device, marking a significant advancement in skin cancer detection. This handheld, non-invasive device utilizes elastic scattering spectroscopy to analyze suspicious skin lesions, providing real-time, objective results to primary care physicians.
Companies are launching advanced AI systems to enhance oncology care. These AI-driven technologies are transforming radiation therapy and personalized treatment pathways, offering more precise and efficient care for both clinicians and patients.
For instance, in May 2024, GE HealthCare unveiled Revolution RT, a cutting-edge radiation therapy CT solution designed to improve imaging accuracy and streamline simulation workflows for a more personalized oncology care experience. The new system, showcased at the ESTRO 2024 Congress in Glasgow, also includes an updated, AI-enhanced version of the Intelligent Radiation Therapy (iRT) platform, which integrates with the Spectronic MRI Planner.
Asia-Pacific is expected to hold 26.8% of the global AI in oncology market.
The Asia-Pacific region is experiencing the fastest growth in the AI in oncology market, fueled by rising cancer rates, advancements in healthcare digitalization, and substantial investments in AI research and technology. Countries such as China, Japan, and India are at the forefront of this growth, driven by expanding healthcare infrastructures and government initiatives that support the integration of AI in cancer care. These countries are also making significant progress in developing AI-powered diagnostic tools and personalized treatment solutions, creating ample opportunities for stakeholders and driving innovation across the region.
Japan, in particular, is playing a key role in advancing AI in oncology. The country is leveraging its technological expertise to integrate AI into cancer care, with notable developments such as Fujifilm's AI-based imaging technology, which helps detect early-stage lung cancer through chest X-rays.
Global AI in Oncology Market Competitive Landscape
The top companies in the AI in oncology market include Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, Tempus, among others.
Global AI in Oncology Market Key Developments
The global AI in oncology market size reached US$ 2.43 Billion in 2024 and is expected to reach US$ 22.85 Billion by 2033, growing at a CAGR of 25.3% during the forecast period 2025-2033.
The global AI in oncology market is witnessing rapid growth, fueled by advancements in artificial intelligence technologies, increased cancer prevalence, and a rising emphasis on personalized medicine. Pharmaceutical and healthcare companies invest heavily in AI-driven diagnostic tools, treatment planning systems, and drug discovery platforms. Regulatory bodies also support this shift, with approvals for AI-based cancer detection devices becoming more common.
Collaboration between medical institutions, technology providers, and research organizations is accelerating the integration of AI into clinical practice. Public awareness about early cancer detection is contributing to higher screening rates, while AI enhances the accuracy and speed of diagnosis.
North America currently dominates the global AI in oncology market, driven by its advanced healthcare infrastructure, strong regulatory support, and high adoption of AI technologies in clinical settings. The presence of leading technology firms and frequent collaborations between healthcare providers and AI developers have further accelerated market growth in the region.
Global AI in Oncology Market Dynamics: Drivers & Restraints
Advancements in Artificial Intelligence and Machine Learning are Expected to Drive the AI in Oncology Market
Advancements in artificial intelligence (AI) and machine learning are playing a pivotal role in the growth of the oncology market by boosting diagnostic precision, enabling more personalized treatment strategies, and speeding up the drug discovery process. For example, in September 2024, Immunai Inc. entered into a multi-year partnership with global pharmaceutical leader AstraZeneca. The collaboration will use Immunai’s proprietary AI platform, known as IDE, to support clinical decision-making and increase the chances of success in drug development efforts.
Similarly, Onc.AI is harnessing a leading real-world oncology dataset to build a robust pipeline of AI models aimed at realizing the full potential of precision oncology.
Meanwhile, companies are collaborating to advance their research in incorporating AI in the early diagnosis of various cancers. For instance, in April 2025, Optellum signed an agreement with Bristol Myers Squibb to use AI for early detection and precision lung cancer care. According to the agreement, Optellum will use its AI-powered imaging and clinical decision support platform to assess the real-world impact on patient outcomes.
Data Privacy and Security Concerns are Expected to Hinder the AI in Oncology Market
Data privacy and security concerns are expected to significantly hamper the growth of the AI in oncology market, as the field heavily relies on large volumes of sensitive patient data for effective algorithm training and deployment. The use of such data raises critical challenges around compliance with regulations like HIPAA in the U.S. and GDPR in Europe, which strictly govern how personal health information can be collected, processed, stored, and shared. Any breach or misuse of this data can lead to legal liabilities, loss of patient trust, and reputational damage for healthcare providers and AI developers.
Global AI in Oncology Market Segment Analysis
The global AI in oncology market is segmented based on component type, cancer type, application, end user and region.
Component Type:
The software segment is expected to hold 46.7% of the global AI in Oncology Market
The software segment is expected to dominate the AI in oncology market due to its pivotal role in enabling accurate diagnostics, personalized treatment planning, and efficient clinical workflows. This dominance is reflected in its substantial market share, driven by growing adoption across hospitals and research institutions. Recent innovations further validate this trend.
For instance, in October 2023, Philips’ AI-powered MR imaging technology, combined with Quibim’s AI-driven image analysis software, is designed to support clinicians in providing quicker and more efficient prostate cancer care, addressing workforce shortages, and helping to reduce overall healthcare costs.
Similarly, in August 2023, MVision AI announced the release of version 1.2.4 of its guideline-based automatic segmentation software, now rebranded as Contour+. This updated version introduces new contouring models and enhanced Region-Of-Interest (ROI) operations, expanding its clinical applications. With this release, MVision AI aims to further improve the accuracy and consistency of medical contouring, offering a more advanced and standardized solution for clinicians. The model also allows for standardized contouring required in clinical trials and cancer research.
Such advancements demonstrate how AI software solutions are becoming integral to oncology workflows, making the segment the core driver of technological transformation in cancer care.
Global AI in Oncology Market Geographical Analysis
North America was valued at US$ 0.96 billion in 2024 and is estimated to reach US$ 9.07 billion by 2033, growing at a CAGR of 31.3%
North America is expected to dominate the AI in oncology market due to its advanced healthcare infrastructure, strong research ecosystem, and a high burden of cancer cases. This leadership is reinforced by recent innovations that are rapidly transforming cancer care. For instance, in January 2024, DermaSensor Inc. received FDA clearance for its innovative AI-powered medical device, marking a significant advancement in skin cancer detection. This handheld, non-invasive device utilizes elastic scattering spectroscopy to analyze suspicious skin lesions, providing real-time, objective results to primary care physicians.
Companies are launching advanced AI systems to enhance oncology care. These AI-driven technologies are transforming radiation therapy and personalized treatment pathways, offering more precise and efficient care for both clinicians and patients.
For instance, in May 2024, GE HealthCare unveiled Revolution RT, a cutting-edge radiation therapy CT solution designed to improve imaging accuracy and streamline simulation workflows for a more personalized oncology care experience. The new system, showcased at the ESTRO 2024 Congress in Glasgow, also includes an updated, AI-enhanced version of the Intelligent Radiation Therapy (iRT) platform, which integrates with the Spectronic MRI Planner.
Asia-Pacific is expected to hold 26.8% of the global AI in oncology market.
The Asia-Pacific region is experiencing the fastest growth in the AI in oncology market, fueled by rising cancer rates, advancements in healthcare digitalization, and substantial investments in AI research and technology. Countries such as China, Japan, and India are at the forefront of this growth, driven by expanding healthcare infrastructures and government initiatives that support the integration of AI in cancer care. These countries are also making significant progress in developing AI-powered diagnostic tools and personalized treatment solutions, creating ample opportunities for stakeholders and driving innovation across the region.
Japan, in particular, is playing a key role in advancing AI in oncology. The country is leveraging its technological expertise to integrate AI into cancer care, with notable developments such as Fujifilm's AI-based imaging technology, which helps detect early-stage lung cancer through chest X-rays.
Global AI in Oncology Market Competitive Landscape
The top companies in the AI in oncology market include Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, Tempus, among others.
Global AI in Oncology Market Key Developments
- In February 2025, Avitia announced its business launch and $5M seed investment from PacBridge Capital Partners (“PacBridge”). With Avitia’s platform, laboratories and clinicians now have access to advanced molecular testing directly on-site. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster, all at reduced costs compared to existing send-out alternatives.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Component Type
2.4. Snippet by Cancer Type
2.5. Snippet by Application
2.6. Snippet by End User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in AI and Machine Learning
3.1.1.2. Increasing Cancer Incidence
3.1.2. Restraints
3.1.2.1. High Cost of AI Systems
3.1.2.2. Data Privacy and Security Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Tele-oncology and Remote Monitoring
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. AI IN ONCOLOGY MARKET COMPONENT TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
5.1.2. Market Attractiveness Index, By Component Type
5.2. Software*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Hardware
5.4. Services
6. AI IN ONCOLOGY MARKET CANCER TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Prostate Cancer
6.5. Skin Cancer
6.6. Others
7. AI IN ONCOLOGY MARKET APPLICATION OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Cancer Detection*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Drug Discovery
7.4. Drug Development
7.5. Others
8. AI IN ONCOLOGY MARKET END USER OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pharmaceutical Companies
8.4. Research Institutes
8.5. Others
9. AI IN ONCOLOGY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
Key Players
11.1. Azra Al*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. CureMetrix, Inc.
11.3. ConcertAI
11.4. Immunai
11.5. MVision AI Inc.
11.6. Paige AI, Inc.
11.7. Mindpeak GmbH
11.8. Imagene AI Ltd.
11.9. Predictive Oncology
11.10. Tempus
Emerging Players
11.11. Insilico Medicine
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Component Type
2.4. Snippet by Cancer Type
2.5. Snippet by Application
2.6. Snippet by End User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in AI and Machine Learning
3.1.1.2. Increasing Cancer Incidence
3.1.2. Restraints
3.1.2.1. High Cost of AI Systems
3.1.2.2. Data Privacy and Security Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Tele-oncology and Remote Monitoring
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. AI IN ONCOLOGY MARKET COMPONENT TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
5.1.2. Market Attractiveness Index, By Component Type
5.2. Software*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Hardware
5.4. Services
6. AI IN ONCOLOGY MARKET CANCER TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Prostate Cancer
6.5. Skin Cancer
6.6. Others
7. AI IN ONCOLOGY MARKET APPLICATION OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Cancer Detection*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Drug Discovery
7.4. Drug Development
7.5. Others
8. AI IN ONCOLOGY MARKET END USER OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pharmaceutical Companies
8.4. Research Institutes
8.5. Others
9. AI IN ONCOLOGY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
Key Players
11.1. Azra Al*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. CureMetrix, Inc.
11.3. ConcertAI
11.4. Immunai
11.5. MVision AI Inc.
11.6. Paige AI, Inc.
11.7. Mindpeak GmbH
11.8. Imagene AI Ltd.
11.9. Predictive Oncology
11.10. Tempus
Emerging Players
11.11. Insilico Medicine
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Al in Oncology Market Value, By Component Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Al in Oncology Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Al in Oncology Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Al in Oncology Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Al in Oncology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Al in Oncology Market Value, By Component Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 8 Global Al in Oncology Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 10 Global Al in Oncology Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Al in Oncology Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Al in Oncology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Al in Oncology Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 17 North America Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 North America Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 22 South America Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 South America Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 South America Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 South America Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 27 Europe Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 28 Europe Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Europe Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Europe Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 41: Azra Al: Overview
Table 42: Azra Al: Product Portfolio
Table 43: Azra Al: Key Developments
Table 44: CureMetrix, Inc.: Overview
Table 45: CureMetrix, Inc.: Product Portfolio
Table 46: CureMetrix, Inc.: Key Developments
Table 47 ConcertAI: Overview
Table 48 ConcertAI: Product Portfolio
Table 49 ConcertAI: Key Developments
Table 50 Immunai: Overview
Table 51 Immunai: Product Portfolio
Table 52 Immunai: Key Developments
Table 53 MVision AI Inc.: Overview
Table 54 MVision AI Inc.: Product Portfolio
Table 55 MVision AI Inc.: Key Developments
Table 56 Paige AI, Inc.: Overview
Table 57 Paige AI, Inc.: Product Portfolio
Table 58 Paige AI, Inc.: Key Developments
Table 59 Mindpeak GmbH: Overview
Table 60 Mindpeak GmbH: Product Portfolio
Table 61 Mindpeak GmbH: Key Developments
Table 62 Imagene AI Ltd.: Overview
Table 63 Imagene AI Ltd.: Product Portfolio
Table 64 Imagene AI Ltd.: Key Developments
Table 65 Predictive Oncology: Overview
Table 66 Predictive Oncology: Product Portfolio
Table 67 Predictive Oncology: Key Developments
Table 68 Tempus: Overview
Table 69 Tempus: Product Portfolio
Table 70 Tempus: Key Developments
Table 1 Global Al in Oncology Market Value, By Component Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Al in Oncology Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Al in Oncology Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Al in Oncology Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Al in Oncology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Al in Oncology Market Value, By Component Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 8 Global Al in Oncology Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 10 Global Al in Oncology Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Al in Oncology Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Al in Oncology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Al in Oncology Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 17 North America Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 North America Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 22 South America Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 South America Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 South America Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 South America Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 27 Europe Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 28 Europe Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Europe Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Europe Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Al in Oncology Market Value, By Component Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Al in Oncology Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Al in Oncology Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Al in Oncology Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Al in Oncology Market Value, By Country, 2022-2033 (US$ Billion)
Table 41: Azra Al: Overview
Table 42: Azra Al: Product Portfolio
Table 43: Azra Al: Key Developments
Table 44: CureMetrix, Inc.: Overview
Table 45: CureMetrix, Inc.: Product Portfolio
Table 46: CureMetrix, Inc.: Key Developments
Table 47 ConcertAI: Overview
Table 48 ConcertAI: Product Portfolio
Table 49 ConcertAI: Key Developments
Table 50 Immunai: Overview
Table 51 Immunai: Product Portfolio
Table 52 Immunai: Key Developments
Table 53 MVision AI Inc.: Overview
Table 54 MVision AI Inc.: Product Portfolio
Table 55 MVision AI Inc.: Key Developments
Table 56 Paige AI, Inc.: Overview
Table 57 Paige AI, Inc.: Product Portfolio
Table 58 Paige AI, Inc.: Key Developments
Table 59 Mindpeak GmbH: Overview
Table 60 Mindpeak GmbH: Product Portfolio
Table 61 Mindpeak GmbH: Key Developments
Table 62 Imagene AI Ltd.: Overview
Table 63 Imagene AI Ltd.: Product Portfolio
Table 64 Imagene AI Ltd.: Key Developments
Table 65 Predictive Oncology: Overview
Table 66 Predictive Oncology: Product Portfolio
Table 67 Predictive Oncology: Key Developments
Table 68 Tempus: Overview
Table 69 Tempus: Product Portfolio
Table 70 Tempus: Key Developments
LIST OF FIGURES
Figure 1 Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 3 Global Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Al in Oncology Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Al in Oncology Market Y-o-Y Growth, By Component Type, 2023-2033 (%)
Figure 8 Software Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 9 Hardware Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 10 Services Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Al in Oncology Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 12 Breast Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 13 Lung Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 14 Prostate Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 15 Skin Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 16: Other Cancer Types in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Al in Oncology Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Cancer Detection Application in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Discovery Application in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 20 Drug Development Application in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 21: Others Application in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Al in Oncology Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 23 Hospitals End User in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 24 Pharmaceutical Companies End User in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 25 Research Institutes End User in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 26: Other End User in the Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 27 Global Al in Oncology Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 28 North America Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 29 North America Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 30 North America Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 31 North America Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 32 North America Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 33 North America Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 34 South America Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 35 South America Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 36 South America Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 37 South America Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 38 South America Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 39 South America Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 40 Europe Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 41 Europe Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 42 Europe Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 43 Europe Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 44 Europe Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 45 Europe Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 46 Asia-Pacific Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 47 Asia-Pacific Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 48 Asia-Pacific Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 49 Asia-Pacific Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 50 Asia-Pacific Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 51 Asia-Pacific Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 52 Middle East and Africa Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 53 Middle East and Africa Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 54 Middle East and Africa Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 56 Middle East and Africa Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 57: Azra Al: Financials
Figure 58: CureMetrix, Inc.: Financials
Figure 59 ConcertAI: Financials
Figure 60 Immunai: Financials
Figure 61: MVision AI Inc.: Financials
Figure 62 Paige AI, Inc.: Financials
Figure 63 Mindpeak GmbH: Financials
Figure 64 Imagene AI Ltd.: Financials
Figure 65 Predictive Oncology: Financials
Figure 66 Tempus: Financials
Figure 1 Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 3 Global Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Al in Oncology Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Al in Oncology Market Y-o-Y Growth, By Component Type, 2023-2033 (%)
Figure 8 Software Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 9 Hardware Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 10 Services Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 11 Global Al in Oncology Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 12 Breast Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 13 Lung Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 14 Prostate Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 15 Skin Cancer Cancer Type in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 16: Other Cancer Types in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Al in Oncology Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Cancer Detection Application in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Discovery Application in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 20 Drug Development Application in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 21: Others Application in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Al in Oncology Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 23 Hospitals End User in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 24 Pharmaceutical Companies End User in Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 25 Research Institutes End User in Global AI in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 26: Other End User in the Global Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 27 Global Al in Oncology Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 28 North America Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 29 North America Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 30 North America Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 31 North America Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 32 North America Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 33 North America Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 34 South America Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 35 South America Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 36 South America Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 37 South America Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 38 South America Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 39 South America Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 40 Europe Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 41 Europe Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 42 Europe Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 43 Europe Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 44 Europe Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 45 Europe Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 46 Asia-Pacific Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 47 Asia-Pacific Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 48 Asia-Pacific Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 49 Asia-Pacific Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 50 Asia-Pacific Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 51 Asia-Pacific Al in Oncology Market Share, By Country, 2024 & 2033 (%)
Figure 52 Middle East and Africa Al in Oncology Market Value, 2022-2033 (US$ Billion)
Figure 53 Middle East and Africa Al in Oncology Market Share, By Component Type, 2024 & 2033 (%)
Figure 54 Middle East and Africa Al in Oncology Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Al in Oncology Market Share, By Application, 2024 & 2033 (%)
Figure 56 Middle East and Africa Al in Oncology Market Share, By End User, 2024 & 2033 (%)
Figure 57: Azra Al: Financials
Figure 58: CureMetrix, Inc.: Financials
Figure 59 ConcertAI: Financials
Figure 60 Immunai: Financials
Figure 61: MVision AI Inc.: Financials
Figure 62 Paige AI, Inc.: Financials
Figure 63 Mindpeak GmbH: Financials
Figure 64 Imagene AI Ltd.: Financials
Figure 65 Predictive Oncology: Financials
Figure 66 Tempus: Financials
